Lanifibranor - Inventiva Pharma

Drug Profile

Lanifibranor - Inventiva Pharma

Alternative Names: IVA 337

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inventiva Pharma
  • Class Antifibrotics; Skin disorder therapies
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis; Systemic scleroderma
  • Preclinical Fibrosis
  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 17 Oct 2017 Inventiva Pharma completes enrolment in the FASST trial for Systemic scleroderma in France, Spain, Germany, Slovenia, Netherlands, Bulgaria, United Kingdom, Switzerland, Poland and Italy
  • 05 Oct 2017 Chemical structure information added
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top